Creative Biolabs’ Comprehensive Services Regarding Oncolytic Virus Construction with OncoVirapy™ Platform

Creative Biolabs is bending efforts to improve the Oncolytic Virus (OV) Therapy by taking advantage of the advanced OncoVirapy™ platform that can operates virus engineering, cell biology and animal testing with a special emphasis on virus engineering and in vitro and in vivo validation.

New York, US – June 27, 2019 – Creative Biolabs’ scientists are devoted to the engineering and design of a fully potential therapeutic OV with the advanced OncoVirapy™ that contains a full set of oncolytic viruses engineering system to shorten the time and cut the budget of OV development, including Oncolytic Virus Construction, Engineering, Validation, and Disease-specific Oncolytic Virotherapy Development.

A wide scope of OVs can be constructed under support of the GMP certified OncoVirapy™, which include but are not limit to Adenovirus, Herpes Simplex Virus, Measles Virus, Vaccinia Virus, Vesicular Stomatitis Virus, and Adeno-Associated Virus, etc.

Oncolytic Adenovirus

Generally used both in experiment as a tool and in gene therapy development as a therapeutic gene delivery vehicle, Adenovirus (Ad) has been proved to be capable of facilitating the design of oncolytic or tumor-selective recombinants. Through OncoVirapy™, the most efficacious adenovirus-based oncolytic viral vector can be generated with three major aspects of engineering to be taken into consideration, i.e. tumor selectivity, oncolytic efficacy and tumor infectivity.

Oncolytic Herpes Simplex Virus

Designing, engineering and generating the most efficacious oncolytic herpes viral vector and viral particles become possible with the help of Creative Biolabs’ one-stop Armed Oncolytic Herpes Simplex Virus construction service, through adopting the technical oncolytic virus development platform.

Oncolytic Vaccinia Virus

Vaccinia virus as a tool for transmitting genes to cancer cells has shown good clinical efficacy not only in medical laboratories, but also in phase I and II trials. By mutation of thymidine kinase (TK) and vaccinia virus growth factor (VGF) on the basis of OncoVirapy™ platform, vaccinia virus can be designed as OV to reduce pathogenicity and increase tumor-specific replication. 

Oncolytic Vesicular Stomatitis Virus (VSV)

Creative Biolabs offers customized, standardized and high-quality oncolytic vesicular stomatitis virus expressing antibody for clients globally to meet their strict requirements and high standard.

Oncolytic Measles Virus (MV)

Customized armed oncolytic measles virus and proof-of-concept validation study for the OVs are provided to help clients achieve research and treatment purpose.

Customers’ projects about oncolytic virus construction afford Creative Biolabs an opportunity to reveal the real strength in area of OV construction with its state-of-the-art OncoVirapy™ platform, on which featured services including Oncolytic Virus Engineering, Validation, and Disease-specific Oncolytic Virotherapy Development can be operated to guarantee a perfect result.

Detailed information and instructions for contact can be found at

About Creative Biolabs

Creative Biolabs has a history of over 10 years working on improving virotherapy, especially in oncolytic virus therapy development, which deserves the rightful status of leadership globally with the advanced technologies and first-level-standard customer-focused service. 

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States